RFS at 12 months among YA patients receiving tisa-cel compared with those receiving brexu-cel. RFS was 36% for YA patients receiving tisa-cel (95% CI, 26-52) and 46% for those receiving brexu-cel 46% (95% CI, 31-81); HR, 1.12; 95% CI, 0.50-2.54; P = .79. RFS was censored for allogeneic stem cell transplant in remission and last follow-up.